Routine Dementia Screening Shows No Benefit or Harm for Family Members

The Clinical Utility of Early Cognitive Screening

The clinical management of Alzheimer disease and related dementias is increasingly focused on early identification within the disease continuum [1]. Current diagnostic frameworks for mild cognitive impairment (a state where cognitive deterioration is present but activities of daily living remain largely preserved) emphasize the importance of informant reports and objective testing [2]. While comprehensive geriatric assessments often incorporate screening to identify syndromes like sarcopenia (the age-related loss of skeletal muscle mass and strength) or cognitive decline, the utility of routine screening in asymptomatic populations remains a subject of debate among guideline committees [1, 3]. Clinicians must frequently balance the potential for early non-pharmacological interventions with the practical realities of long-term implementation in the home setting [4]. A recent large-scale randomized trial now examines how these screening practices specifically impact the health and readiness of the patients' family members.

Trial Design and Dyad Characteristics

This multisite randomized clinical trial was conducted across 29 primary care clinics between October 2018 and September 2023 to evaluate the impact of cognitive screening on the family unit. The study enrolled a total of 1808 dyads, each consisting of a patient aged 65 years or older and a corresponding family member, all of whom completed baseline assessments. These dyads were randomized into one of three distinct study arms: a screening-only group, a group receiving screening plus a referral for diagnostic follow-up if indicated, and a no-screening control group. The researchers utilized several validated instruments to assess cognitive status, including the Mini-Cog, the Memory Impairment Screen Telephone version (MIS-T), or the MIS-T supplemented with a clock drawing test (a brief cognitive assessment where a patient draws a clock face to evaluate executive function and visuospatial skills). These assessments were administered through various modalities to reflect modern clinical practice, including in-person visits, telephone calls, or secure video conferencing. The patient population had a mean age of 73.7 years (SD 5.7), and 959 patients (53%) were female. The family members involved in the study had a mean age of 64.2 years (SD 12.9), and the majority were female, totaling 1224 individuals (67.7%). Regarding the relationship dynamics within the dyads, 1171 family members (64.8%) were spouses of the patients being screened. By including a high proportion of spousal caregivers and utilizing a randomized three-arm design, the trial aimed to provide a rigorous assessment of whether identifying cognitive impairment in a primary care setting translates to measurable changes in the psychological well-being or preparedness of those most closely involved in the patient's daily care.

Impact on Quality of Life and Psychological Well-being

The researchers evaluated the benefits and risks of Alzheimer disease and related dementias screening for family members of older adults screened in primary care, collecting data at baseline and at 6, 12, 18, and 24 months. The primary outcome was family member health-related quality of life at 24 months measured using the Short Form Health Survey (SF-36) physical and mental component summary scores. Analysis of the data showed that there were no significant differences between the combined screening groups and the no-screening group in SF-36 physical component scores, with a 24-month predicted difference of -0.21 (95% CI, -1.26 to 0.85). Similarly, no significant differences were observed in SF-36 mental component scores, which yielded a 24-month predicted difference of 0.58 (95% CI, -0.18 to 1.33). Secondary outcomes for family members included depressive and anxiety symptoms, caregiver preparedness (the perceived readiness to manage the physical and emotional demands of caregiving), and caregiving self-efficacy (the level of confidence a person has in their ability to perform specific caregiving tasks). The study found that screening was not associated with improvements or declines in these measures. For the practicing physician, these results suggest that the act of screening does not inherently increase psychological distress or improve the family's sense of readiness for the caregiving role. Patient secondary outcomes, which included health-related quality of life as well as depressive and anxiety symptoms, were also tracked throughout the study period. No differences were observed in patient secondary outcomes at 24 months, specifically regarding health-related quality of life, depressive symptoms, and anxiety symptoms. These findings indicate that routine cognitive screening in a primary care setting does not appear to alter the psychological trajectory or quality of life for either the patient or their family member over a two-year follow-up period.

Barriers to Diagnostic Follow-up and Clinical Implications

The clinical utility of routine screening is often limited by the actual yield of positive cases and the subsequent uptake of diagnostic services. In this study, overall, 62 patients (5.1%) screened positive for cognitive impairment, a relatively low prevalence that may influence the perceived necessity of universal screening programs in primary care settings. Furthermore, even when a positive screen was identified and a referral was made, significant barriers to further evaluation remained. Among dyads assigned to screen plus (screening plus referral for diagnostic follow-up), 10 (35.7%) did not pursue diagnostic follow-up, suggesting that a substantial portion of patients or their families may be hesitant to engage in the formal diagnostic process even after an initial screening indicates potential impairment. For the practicing physician, these findings clarify the psychological and functional impact of screening on the family unit. The data demonstrated that screening was not associated with improvement in family member health-related quality of life, caregiver preparedness, or caregiving self-efficacy. This indicates that the simple act of identifying potential cognitive decline does not automatically translate into better-prepared caregivers or improved family well-being. Conversely, the study provides reassurance regarding the potential for psychological harm, as screening was not associated with increased family member depression or anxiety. These results suggest that while routine screening does not appear to cause immediate psychological distress, it also fails to provide the anticipated benefits of early preparation or enhanced self-efficacy for family members, particularly when follow-up diagnostic rates remain low.

References

1. Monfared AAT, Phan NTN, Pearson I, et al. A Systematic Review of Clinical Practice Guidelines for Alzheimer’s Disease and Strategies for Future Advancements. Neurological Therapeutics. 2023. doi:10.1007/s40120-023-00504-6

2. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine. 2004. doi:10.1111/j.1365-2796.2004.01380.x

3. Cruz‐Jentoft AJ, Baeyens J, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis. Age and Ageing. 2010. doi:10.1093/ageing/afq034

4. Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. The British Journal of Psychiatry. 2014. doi:10.1192/bjp.bp.113.141119